APA
Eggermont A. M. M., Blank C. U., Mandala M., Long G. V., Atkinson V. G., Dalle S., Haydon A., Lichinitser M., Khattak A., Carlino M. S., Sandhu S., Larkin J., Puig S., Ascierto P. A., Rutkowski P., Schadendorf D., Koornstra R., Hernandez-Aya L., Di Giacomo A. M., van den Eertwegh A. J., Grob J., Gutzmer R., Jamal R., Lorigan P. C., Lupinacci R., Krepler C., Ibrahim N., Kicinski M., Marreaud S., van Akkooi A. C., Suciu S. & Robert C. (20200601). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. : European journal of cancer (Oxford, England : 1990).
Chicago
Eggermont Alexander M M, Blank Christian U, Mandala Mario, Long Georgina V, Atkinson Victoria G, Dalle Stéphane, Haydon Andrew, Lichinitser Mikhail, Khattak Adnan, Carlino Matteo S, Sandhu Shahneen, Larkin James, Puig Susana, Ascierto Paolo A, Rutkowski Piotr, Schadendorf Dirk, Koornstra Rutger, Hernandez-Aya Leonel, Di Giacomo Anna Maria, van den Eertwegh Alfonsus Jm, Grob Jean-Jacques, Gutzmer Ralf, Jamal Rahima, Lorigan Paul C, Lupinacci Robert, Krepler Clemens, Ibrahim Nageatte, Kicinski Michal, Marreaud Sandrine, van Akkooi Alexander C, Suciu Stefan and Robert Caroline. 20200601. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. : European journal of cancer (Oxford, England : 1990).
Harvard
Eggermont A. M. M., Blank C. U., Mandala M., Long G. V., Atkinson V. G., Dalle S., Haydon A., Lichinitser M., Khattak A., Carlino M. S., Sandhu S., Larkin J., Puig S., Ascierto P. A., Rutkowski P., Schadendorf D., Koornstra R., Hernandez-Aya L., Di Giacomo A. M., van den Eertwegh A. J., Grob J., Gutzmer R., Jamal R., Lorigan P. C., Lupinacci R., Krepler C., Ibrahim N., Kicinski M., Marreaud S., van Akkooi A. C., Suciu S. and Robert C. (20200601). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. : European journal of cancer (Oxford, England : 1990).
MLA
Eggermont Alexander M M, Blank Christian U, Mandala Mario, Long Georgina V, Atkinson Victoria G, Dalle Stéphane, Haydon Andrew, Lichinitser Mikhail, Khattak Adnan, Carlino Matteo S, Sandhu Shahneen, Larkin James, Puig Susana, Ascierto Paolo A, Rutkowski Piotr, Schadendorf Dirk, Koornstra Rutger, Hernandez-Aya Leonel, Di Giacomo Anna Maria, van den Eertwegh Alfonsus Jm, Grob Jean-Jacques, Gutzmer Ralf, Jamal Rahima, Lorigan Paul C, Lupinacci Robert, Krepler Clemens, Ibrahim Nageatte, Kicinski Michal, Marreaud Sandrine, van Akkooi Alexander C, Suciu Stefan and Robert Caroline. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. : European journal of cancer (Oxford, England : 1990). 20200601.